Review of hepatobiliary contrast agents: Current applications and challenges
Alex Frydrychowicz – 31 January 2018
Intra‐arterial locoregional therapy in the management of hepatocellular carcinoma
Meera Ramanathan, Anil Seetharam – 31 January 2018
Intra‐arterial locoregional therapy in the management of hepatocellular carcinoma
Meera Ramanathan, Anil Seetharam – 31 January 2018
Clinical studies investigating the effect of vitamin E therapy in patients with NASH
- Read more about Clinical studies investigating the effect of vitamin E therapy in patients with NASH
Sebastian Larion, Sandeep Khurana – 31 January 2018
Correction
31 January 2018
Proton pump inhibitors, Enterococcus, and the liver, oh my!
Rotonya M. Carr – 30 January 2018
A novel transforming growth factor beta‐induced long noncoding RNA promotes an inflammatory microenvironment in human intrahepatic cholangiocarcinoma
Aude Merdrignac, Gaëlle Angenard, Coralie Allain, Kilian Petitjean, Damien Bergeat, Pascale Bellaud, Allain Fautrel, Bruno Turlin, Bruno Clément, Steven Dooley, Laurent Sulpice, Karim Boudjema, Cédric Coulouarn – 30 January 2018 – Intrahepatic cholangiocarcinoma (iCCA) is a deadly liver primary cancer associated with poor prognosis and limited therapeutic opportunities. Active transforming growth factor beta (TGFβ) signaling is a hallmark of the iCCA microenvironment. However, the impact of TGFβ on the transcriptome of iCCA tumor cells has been poorly investigated.
Less can be more: A finite treatment approach for HBeAg‐negative chronic hepatitis B
- Read more about Less can be more: A finite treatment approach for HBeAg‐negative chronic hepatitis B
Pietro Lampertico, Thomas Berg – 30 January 2018
Tumor Progression Locus 2 in Hepatocytes Potentiates Both Liver and Systemic Metabolic Disorders in Mice
Jun Gong, Chun Fang, Peng Zhang, Pi‐Xiao Wang, Yixing Qiu, Li‐Jun Shen, Li Zhang, Xue‐Yong Zhu, Song Tian, Feng Li, Zhihua Wang, Zan Huang, Aibing Wang, Xiao‐Dong Zhang, Zhi‐Gang She – 30 January 2018 – Tumor progression locus 2 (TPL2), a serine/threonine kinase, has been regarded as a potentially interesting target for the treatment of various diseases with an inflammatory component. However, the function of TPL2 in regulating hepatocyte metabolism and liver inflammation during the progression of nonalcoholic fatty liver disease (NAFLD) is poorly understood.
Targeting Pin1 by inhibitor API‐1 regulates microRNA biogenesis and suppresses hepatocellular carcinoma development
Wenchen Pu, Jiao Li, Yuanyuan Zheng, Xianyan Shen, Xin Fan, Jian‐Kang Zhou, Juan He, Yulan Deng, Xuesha Liu, Chun Wang, Shengyong Yang, Qiang Chen, Lunxu Liu, Guolin Zhang, Yu‐Quan Wei, Yong Peng – 30 January 2018 – Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide, but there are few effective treatments. Aberrant microRNA (miRNA) biogenesis is correlated with HCC development. We previously demonstrated that peptidyl‐prolyl cis‐trans isomerase NIMA‐interacting 1 (Pin1) participates in miRNA biogenesis and is a potential HCC treatment target.